Toric IOLs reduce astigmatism more than PCRIs

Article

Both toric IOLs and peripheral corneal relaxing incisions (PCRIs) reduce astigmatism, but toric IOLs do so to a greater extent as well as being more predictable, according to results of a recently published study.

Both toric IOLs and peripheral corneal relaxing incisions (PCRIs) reduce astigmatism, but toric IOLs do so to a greater extent as well as being more predictable, according to results of a study recently published in the Journal of Cataract & Refractive Surgery.

For this prospective masked bilateral randomized study, researchers from Moorfields Eye Hospital NHS Foundation Trust, London, enrolled 30 patients (60 eyes) with a preoperative corneal astigmatism of 1.0 to 2.5 D. All patients received a toric IOL in one eye and nontoric IOL plus PCRI in the other eye. Postoperative follow-up was done at 1 hour, 1 month and 6 months to measure uncorrected distance visual acuity, corrected distance visual acuity, autorefraction and subjective refraction. The IOL axis was assessed with retroillumination photos.

Researchers found a statistically significant difference in the mean astigmatism vector reduction in the toric IOL group compared with the PCRI group (1.74 D vs 1.27 D, respectively; P = 0.042). Mean absolute rotation of the toric IOL was 2.5 degrees (maximum 6.3 degrees) in the first 6 months postoperatively. Astigmatism increased in the PCRI group between the 1-month and the 6-month follow-up (mean: 0.38 D; maximum: 1.00 D; P

To view the abstract of this study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.